Amoéba has received marketing authorisation in France for AXPERA, its biofungicide based on the lysate of the Willaertia magna C2c Maky amoeba, confirming a key regulatory catalyst flagged in our FY25 note. This is the company’s first long-term product authorisation in Europe and moves AXPERA from
